WuXi Biologics, a global contract research, development, and manufacturing organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies, signed a memorandum of understanding (MOU) for research and discovery services for Boostimmune's pipeline.

Under the alliance, Boostimmune will have access to WuXi Biologics' discovery services and expertise in antibody discovery, lead optimization, in vitro screening, and characterization, as well as in vivo tests. WuXi Biologics will be the exclusive service partner to support Boostimmune in generating different modality candidates, including monoclonal antibodies, bispecific antibodies, and recombinant proteins.

Gwanghee Lee, Co-founder and CEO of Boostimmune, said, "Collaborating with WuXi Biologics - and accessing their comprehensive antibody generation technology platform - offers an opportunity to discover novel biological candidates and explore the science of complex proteins. We look forward to working with WuXi Biologics to build a compelling pipeline with the potential to meaningfully improve the lives of patients."

Chris Chen, CEO of WuXi Biologics, said, "We are very pleased to partner with Boostimmune to advance their innovative pipeline. The biotech industry in South Korea is flourishing, and there is increasing demand for end-to-end discovery and development services. WuXi Biologics is proud to support our global and Asia partners in bringing innovative biologics solutions to market for patients around the world."